PMID- 17651772 OWN - NLM STAT- MEDLINE DCOM- 20071128 LR - 20211203 IS - 0041-008X (Print) IS - 0041-008X (Linking) VI - 224 IP - 2 DP - 2007 Oct 15 TI - MAPK-ERK activation in kidney of male rats chronically fed ochratoxin A at a dose causing a significant incidence of renal carcinoma. PG - 174-81 AB - Kidney samples of male Fischer 344 (F-344) rats fed a carcinogenic dose of OTA over 7 days, 21 days and 12 months were analysed for various cell signalling proteins known to be potentially involved in chemical carcinogenicity. OTA was found to increase the phosphorylation of atypical-PKC. This was correlated with a selective downstream activation of the MAP-kinase extracellular regulated kinases isoforms 1 and 2 (ERK1/2) and of their substrates ELK1/2 and p90RSK. Moreover, analysis of effectors acting upstream of PKC indicated a possible mobilisation of the insulin-like growth factor-1 receptor (lGFr) and phosphoinositide-dependent kinase-1 (PDK1) system. An increased histone deacetylase (HDAC) enzymatic activity associated with enhanced HDAC3 protein expression was also observed. These findings are potentially relevant with respect to the understanding of OTA nephrocarcinogenicity. HDAC-induced gene silencing has previously been shown to play a role in tumour development. Furthermore, PKC and the MEK-ERK MAP-kinase pathways are known to play important roles in cell proliferation, cell survival, anti-apoptotic activity and renal cancer development. FAU - Marin-Kuan, M AU - Marin-Kuan M AD - Nestle Research Center, PO Box 44, Vers-chez-les-Blanc, CH-1000 Lausanne 26, Switzerland. maricel.marin-kuan@rdls.nestle.com FAU - Nestler, S AU - Nestler S FAU - Verguet, C AU - Verguet C FAU - Bezencon, C AU - Bezencon C FAU - Piguet, D AU - Piguet D FAU - Delatour, T AU - Delatour T FAU - Mantle, P AU - Mantle P FAU - Cavin, C AU - Cavin C FAU - Schilter, B AU - Schilter B LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20070703 PL - United States TA - Toxicol Appl Pharmacol JT - Toxicology and applied pharmacology JID - 0416575 RN - 0 (Carcinogens) RN - 0 (Elk1 protein, rat) RN - 0 (Ochratoxins) RN - 0 (ets-Domain Protein Elk-1) RN - 1779SX6LUY (ochratoxin A) RN - EC 2.7.10.1 (Receptor, IGF Type 1) RN - EC 2.7.11.1 (3-Phosphoinositide-Dependent Protein Kinases) RN - EC 2.7.11.1 (Pdpk1 protein, rat) RN - EC 2.7.11.1 (Protein Serine-Threonine Kinases) RN - EC 2.7.11.1 (Ribosomal Protein S6 Kinases, 90-kDa) RN - EC 2.7.11.24 (Mitogen-Activated Protein Kinase 1) RN - EC 2.7.11.24 (Mitogen-Activated Protein Kinase 3) RN - EC 3.5.1.98 (Histone Deacetylases) RN - EC 3.5.1.98 (histone deacetylase 3) SB - IM MH - 3-Phosphoinositide-Dependent Protein Kinases MH - Animals MH - Blotting, Western MH - Carcinogens/administration & dosage/*toxicity MH - Gene Expression Regulation/drug effects MH - Histone Deacetylases/metabolism MH - Kidney/metabolism MH - Kidney Neoplasms/chemically induced/physiopathology MH - MAP Kinase Signaling System/drug effects MH - Male MH - Mitogen-Activated Protein Kinase 1/*drug effects/metabolism MH - Mitogen-Activated Protein Kinase 3/*drug effects/metabolism MH - Ochratoxins/administration & dosage/*toxicity MH - Phosphorylation MH - Protein Serine-Threonine Kinases/drug effects/metabolism MH - Rats MH - Rats, Inbred F344 MH - Receptor, IGF Type 1/drug effects/metabolism MH - Ribosomal Protein S6 Kinases, 90-kDa/drug effects/metabolism MH - Time Factors MH - ets-Domain Protein Elk-1/drug effects/metabolism EDAT- 2007/07/27 09:00 MHDA- 2007/12/06 09:00 CRDT- 2007/07/27 09:00 PHST- 2006/11/21 00:00 [received] PHST- 2007/05/16 00:00 [revised] PHST- 2007/06/26 00:00 [accepted] PHST- 2007/07/27 09:00 [pubmed] PHST- 2007/12/06 09:00 [medline] PHST- 2007/07/27 09:00 [entrez] AID - S0041-008X(07)00286-4 [pii] AID - 10.1016/j.taap.2007.06.014 [doi] PST - ppublish SO - Toxicol Appl Pharmacol. 2007 Oct 15;224(2):174-81. doi: 10.1016/j.taap.2007.06.014. Epub 2007 Jul 3.